ArticleHypertension research : official journal of the Japanese Society of Hypertension2022
A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Guidelines for the appropriate use of renal denervation systems in Japan: endorsed by the Japanese Society of Hypertension (JSH), the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS), and their positioning in the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology.Journal of nephrology · 2025Guideline
- Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia.BMC cardiovascular disorders · 2026Article
- Renal Denervation for Uncontrolled Hypertension: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- Renal Denervation in Asia: 2025 Asia Renal Denervation Consortium (ARDeC) Consensus Statement Endorsed by the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Renal denervation for hypertension.Nature reviews. Cardiology · 2025Review
- Evaluating Veterans' Preferences for Renal Denervation for Treatment of Difficult-to-Control Hypertension: A Single-Center Survey Study.Health science reports · 2025Article
- Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment.Journal of hypertension · 2025Article
- Sex-specific differences in the efficacy of renal denervation in patients with resistant hypertension depending on visceral obesity and kidney function.Frontiers in cardiovascular medicine · 2025Article
- Cost-Effectiveness of Radiofrequency Renal Denervation for Uncontrolled Hypertension in Japan.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Cardiovascular intervention and therapeutics · 2024Article
- Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?).Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- 2023 update and perspectives.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Current problems in renal denervation and a hope to break the stage.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Topics 2023 in Hypertension Research leading to guidelines in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Article
- The denervation or activation of renal sympathetic nerve and renal blood flow.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- A recent advance in Renal denervation to clinical practice.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- 2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal denervation is a potential alternative to antihypertensive drug therapy. However, data on patient preference for this treatment option are limited and there are no data specifically from Asian patients. This study evaluated patient preference for renal denervation in patients with hypertension from Japan. Patients were a subset of those who participated in a March 2020 online electronic survey of patients with hypertension who had regularly visited medical institutions for treatment, were receiving antihypertensive drug therapy and had home blood pressure recordings available. The survey included a question about patient preference for treatment with renal denervation. A total of 2,392 patients were included (66% male, mean age 59.8 ± 11.6 years, mean duration of hypertension 11.4 ± 9.5 years). Preference for renal denervation was expressed by 755 patients (31.6%), and was higher in males than in females, in younger compared with older patients, in those with higher versus lower blood pressure, in patients who were less adherent versus more adherent to antihypertensive drug therapy, and in those who did rather than did not have antihypertensive drug-related side effects. Significant predictors of preference for renal denervation on logistic regression analysis were younger patient age, male sex, higher home or office systolic blood pressure, poor antihypertensive drug adherence, the presence of heart failure, and the presence of side effects during treatment with antihypertensive drugs. Overall, a relevant proportion of Japanese patients with hypertension expressed a preference for renal denervation. This should be taken into account when making shared decisions about antihypertensive drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.